1. WTAP weakens oxaliplatin chemosensitivity of colorectal cancer by preventing PANoptosis.
- Author
-
Tan YT, Li T, Wang RB, Liu ZK, Ma MY, Huang RZ, Mo HY, Luo SY, Lin JF, Xu RH, and Ju HQ
- Subjects
- Humans, RNA Splicing Factors genetics, RNA Splicing Factors metabolism, HCT116 Cells, Animals, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Gene Expression Regulation, Neoplastic drug effects, Oxidative Stress drug effects, Cell Line, Tumor, Mice, Cell Cycle Proteins metabolism, Cell Cycle Proteins genetics, Cell Proliferation drug effects, Adenosine analogs & derivatives, Adenosine pharmacology, Oxaliplatin pharmacology, Colorectal Neoplasms drug therapy, Colorectal Neoplasms pathology, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, NF-E2-Related Factor 2 metabolism, NF-E2-Related Factor 2 genetics, Drug Resistance, Neoplasm drug effects
- Abstract
As the most abundant post-transcriptional modification in eukaryotes, N
6 -methyladenosine (m6 A) plays a crucial role in cancer cell proliferation, invasion and chemoresistance. However, its specific effects on chemosensitivity to oxaliplatin-based regimens and the impact of these drugs on m6 A methylation levels in colorectal cancer (CRC) remain largely unexplored. In this study, we demonstrated that the m6 A methyltransferase Wilms tumor 1-associating protein (WTAP) weakens oxaliplatin chemosensitivity in HCT116 and DLD1 cells. Mechanistically, oxaliplatin treatment upregulated WTAP expression, preventing multiple forms of cell death simultaneously, a process known as PANoptosis, by decreasing intracellular oxidative stress through maintaining the expression of nuclear factor erythroid-2-related factor 2 (NRF2), a major antioxidant response element, in an m6 A-dependent manner. In addition, high WTAP expression in CRC patients is associated with a poor prognosis and reduced benefit from standard chemotherapy by clinical data analysis of The Cancer Genome Atlas (TCGA) database and patient cohort study. These findings suggest that targeting WTAP-NRF2-PANoptosis axis could enhance the antitumor efficacy of oxaliplatin-based chemotherapy in CRC treatment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF